Sutro Historical Financial Ratios
| STRO Stock | USD 2.65 0.04 1.49% |
Sutro Biopharma is promptly reporting on over 101 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 2.1, Invested Capital of 0.0, Average Payables of 0.0 or Stock Based Compensation To Revenue of 0.16 will help investors to properly organize and evaluate Sutro Biopharma financial condition quickly.
Sutro |
About Sutro Financial Ratios Analysis
Sutro BiopharmaFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Sutro Biopharma investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Sutro financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Sutro Biopharma history.
Sutro Biopharma Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Sutro Biopharma stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Sutro Biopharma sales, a figure that is much harder to manipulate than other Sutro Biopharma multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Capex To Depreciation
The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.Most ratios from Sutro Biopharma's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Sutro Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sutro Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.At this time, Sutro Biopharma's Net Debt To EBITDA is very stable compared to the past year. As of the 29th of November 2024, Graham Net Net is likely to grow to 1.42, while Price To Sales Ratio is likely to drop 1.59.
| 2021 | 2022 | 2023 | 2024 (projected) | Graham Number | 17.04 | 15.04 | 9.97 | 9.47 | Receivables Turnover | 4.97 | 9.52 | 4.26 | 4.05 |
Sutro Biopharma fundamentals Correlations
Click cells to compare fundamentals
Sutro Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sutro Biopharma fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 5.91 | 16.55 | 11.09 | 6.05 | 1.68 | 1.59 | |
| Ptb Ratio | 2.58 | 2.13 | 2.72 | 1.89 | 1.72 | 0.93 | |
| Days Sales Outstanding | 53.79 | 47.49 | 73.46 | 38.36 | 85.66 | 89.94 | |
| Book Value Per Share | 4.26 | 10.19 | 5.48 | 4.28 | 2.49 | 2.1 | |
| Free Cash Flow Yield | (0.27) | (0.11) | (0.14) | (0.0105) | (0.45) | (0.43) | |
| Operating Cash Flow Per Share | (2.83) | (2.08) | (1.77) | 0.0699 | (1.86) | (1.95) | |
| Stock Based Compensation To Revenue | 0.0748 | 0.24 | 0.28 | 0.38 | 0.39 | 0.16 | |
| Capex To Depreciation | 0.73 | 1.66 | 3.16 | 1.38 | 0.63 | 0.94 | |
| Pb Ratio | 2.58 | 2.13 | 2.72 | 1.89 | 1.72 | 0.93 | |
| Ev To Sales | 6.02 | 12.3 | 11.53 | 6.35 | 1.45 | 1.37 | |
| Free Cash Flow Per Share | (2.98) | (2.3) | (2.1) | (0.0849) | (1.93) | (2.02) | |
| Roic | (0.6) | (0.22) | (0.36) | (0.55) | (0.67) | (0.71) | |
| Net Income Per Share | (2.43) | (1.11) | (2.36) | (2.35) | (1.78) | (1.86) | |
| Payables Turnover | 11.75 | 13.88 | 1.63 | 1.73 | 0.72 | 0.69 | |
| Sales General And Administrative To Revenue | 0.76 | 0.86 | 0.91 | 0.88 | 0.41 | 0.5 | |
| Research And Ddevelopement To Revenue | 1.54 | 1.8 | 1.69 | 2.02 | 1.17 | 1.14 | |
| Capex To Revenue | 0.0815 | 0.17 | 0.25 | 0.12 | 0.0281 | 0.0267 | |
| Cash Per Share | 5.13 | 11.3 | 4.29 | 6.59 | 6.24 | 10.87 | |
| Pocfratio | (3.88) | (10.43) | (8.4) | 115.52 | (2.31) | (2.2) | |
| Interest Coverage | (12.75) | (17.43) | (31.41) | (38.54) | (3.76) | (3.95) | |
| Capex To Operating Cash Flow | (0.0535) | (0.11) | (0.19) | 2.21 | (0.0387) | (0.0367) | |
| Pfcf Ratio | (3.69) | (9.44) | (7.07) | (95.14) | (2.23) | (2.34) | |
| Days Payables Outstanding | 31.06 | 26.29 | 224.42 | 211.26 | 505.52 | 530.79 | |
| Income Quality | 1.17 | 2.11 | 0.77 | (0.0298) | 1.05 | 1.1 | |
| Roe | (0.57) | (0.11) | (0.43) | (0.55) | (0.71) | (0.68) | |
| Ev To Operating Cash Flow | (3.96) | (7.75) | (8.73) | 121.23 | (1.99) | (1.89) | |
| Pe Ratio | (4.53) | (19.53) | (6.31) | (3.44) | (2.42) | (2.3) | |
| Return On Tangible Assets | (0.36) | (0.0919) | (0.32) | (0.29) | (0.23) | (0.24) | |
| Ev To Free Cash Flow | (3.76) | (7.01) | (7.35) | (99.85) | (1.92) | (2.01) | |
| Earnings Yield | (0.22) | (0.0512) | (0.16) | (0.29) | (0.41) | (0.43) | |
| Net Debt To E B I T D A | 3.37 | (0.11) | 7.65 | (0.27) | (0.19) | 1.01 | |
| Current Ratio | 3.9 | 12.78 | 5.24 | 2.22 | 4.5 | 3.62 | |
| Tangible Book Value Per Share | 4.26 | 10.19 | 5.48 | 4.28 | 2.49 | 2.1 | |
| Receivables Turnover | 6.79 | 7.69 | 4.97 | 9.52 | 4.26 | 4.05 | |
| Graham Number | 15.25 | 15.97 | 17.04 | 15.04 | 9.97 | 9.47 | |
| Shareholders Equity Per Share | 4.26 | 10.19 | 5.48 | 4.28 | 2.49 | 2.1 | |
| Debt To Equity | 0.11 | 0.1 | 0.0739 | 0.0961 | 0.07 | 0.0483 | |
| Capex Per Share | 0.27 | 0.15 | 0.22 | 0.33 | 0.0717 | 0.0681 | |
| Graham Net Net | 2.79 | 9.52 | 2.57 | 2.84 | 1.36 | 1.42 |
Pair Trading with Sutro Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sutro Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sutro Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against Sutro Stock
| 0.63 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.52 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.51 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.46 | BHC | Bausch Health Companies | PairCorr |
| 0.43 | GILD | Gilead Sciences | PairCorr |
The ability to find closely correlated positions to Sutro Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sutro Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sutro Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sutro Biopharma to buy it.
The correlation of Sutro Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sutro Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sutro Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sutro Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sutro Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sutro Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Revenue Per Share 2.253 | Quarterly Revenue Growth (0.50) | Return On Assets (0.18) | Return On Equity (1.11) |
The market value of Sutro Biopharma is measured differently than its book value, which is the value of Sutro that is recorded on the company's balance sheet. Investors also form their own opinion of Sutro Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sutro Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sutro Biopharma's market value can be influenced by many factors that don't directly affect Sutro Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sutro Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.